Fluorometric Assays of Phospholipase A2 Activity with Three Different Substrates in BiologicalSamples of Patients with Schizophrenia
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378879235 | ||
| 003 | CHVBK | ||
| 005 | 20180305123428.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20030721xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/CCLM.2003.138 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/CCLM.2003.138 | ||
| 245 | 0 | 0 | |a Fluorometric Assays of Phospholipase A2 Activity with Three Different Substrates in BiologicalSamples of Patients with Schizophrenia |h [Elektronische Daten] |c [Jürgen Lasch, Ingo Willhardt, Daniel Kinder, Heinrich Sauer, Stefan Smesny] |
| 520 | 3 | |a The rationale of this study was to understand the complexity of kinetics of fluorogenic phospholipid substratesas well as contradictory findings of clinical papers measuring phospholipase A2 (PLA2) activity using different methodologies. The aim was to recommend to clinicians and researchers what substrate in conjunction with what assay should be used. Two methods, (i) continuous fluorometric assay and (ii) high performance thin layer chromatography (HPTLC) on microplates combined with quantitative image scanning, were studied with three different substrates (bis-BODIPY® FL C11-PC, NBDC6-HPC®, PED6®). The study demonstrates that NBD-PC is not a suitable substrate to measure PLA2 activity using a spectrofluorometer. On the other hand, NBD-PC gives the highest and most reproducible integrated light intensities (ILIs) in HPTLC studies. Slow time-dependent increases in fluorescence intensities recorded with biological samples in fluorometers, but not caused by substrate splitting, had to be classified as "perturbation kinetics”. PLA2 activities in blood samples of 26 unmedicated schizophrenia patients and 26 age-matched healthy controls were measured by the spectrofluorometric method and then compared with the activity data obtained with the HPTLC method. A significant group difference was found only with the HPTLC. In order to get more reliable results, we recommend that clinicians and researchers use NBD-phosphatidylcholines as PLA2 substrates in biological samples and start with an analytical separation of reaction products followed by image analysis of the fluorescent spots. | |
| 540 | |a Copyright © 2003 by Walter de Gruyter GmbH & Co. KG | ||
| 690 | 7 | |a Medical equipment & techniques |2 nationallicence | |
| 690 | 7 | |a Medical diagnosis |2 nationallicence | |
| 690 | 7 | |a Diseases & disorders |2 nationallicence | |
| 700 | 1 | |a Lasch |D Jürgen |4 aut | |
| 700 | 1 | |a Willhardt |D Ingo |4 aut | |
| 700 | 1 | |a Kinder |D Daniel |4 aut | |
| 700 | 1 | |a Sauer |D Heinrich |4 aut | |
| 700 | 1 | |a Smesny |D Stefan |4 aut | |
| 773 | 0 | |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/7(2003-07-21), 908-914 |x 1434-6621 |q 41:7<908 |1 2003 |2 41 |o cclm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2003.138 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/CCLM.2003.138 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Lasch |D Jürgen |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Willhardt |D Ingo |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kinder |D Daniel |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sauer |D Heinrich |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Smesny |D Stefan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/7(2003-07-21), 908-914 |x 1434-6621 |q 41:7<908 |1 2003 |2 41 |o cclm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||